anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aerosol spray formulations capable of delivering high concentrations of active agent-containing materials and/or excipient are described herein. The formulation contains a carrier fluid, a propellant and a therapeutic, prophylactic, cosmeticeutical and/or inert solid suspended, dissolved, or dispersed in the formulation. The active ingredient may be an antibiotic, an antihistamine, an anesthetic, an anti-inflammatory, and/or an astringent. In one embodiment, the active agent is an antifungal agent. In another embodiment, the active agent is a cosmeticeutical. The active agent can optionally be dispersed on, or associated with, a carrier powder. The carrier fluid is a highly volatile silicone liquid, which evaporates in less than  10  minutes after application of the formulation to the patient's skin. The formulation may also contain one or more pharmaceutically acceptable excipients The formulation can be packaged in a conventional aerosol spray can.
BACKGROUND: Cardiovascular diseases (CVDs) pose a significant threat to public health. Evidence indicates that the combination of central obesity and normal body mass index (BMI) is associated with an increased risk of cardiovascular disease and mortality. However, limited evidences exists in middle aged and elderly adults in China.
METHODS: This was a prospective cohort study that utilized a nationally representative sample of 6,494 adults aged 45 years and above. These individuals participated in the China Health and Retirement Longitudinal Study spanning from 2011 to 2018. Height, weight and waist circumference (WC) were measured, and BMI was calculated by height and weight. Other variables were obtained through self-reported questionnaires. Association analysis was conducted using Cox proportional hazard regression models.
RESULTS: A total of 10,186 participants were investigated, with 57,185 person-years of follow-up. During this period, 1,571 CVDs occurred, including 1,173 heart diseases and 527 strokes. After adjusting for various factors including age, gender, education, marital status, smoking status, alcohol intake, social activity, hypertension, dyslipidemia, diabetes, cancer, chronic lung diseases, liver disease, kidney disease, digestive disease, ENP(emotional, nervous, or psychiatric problems), memory related disease, arthritis or rheumatism, asthma, self-rated health and depression, the results revealed that compared to those with normal WC normal body mass index (BMI), individuals with central obesity normal BMI had a 27.9% higher risk of CVD incidence (95% confidence interval [CI]:1.074-1.524), and a 33.4% higher risk of heart disease incidence (95% CI:1.095-1.625), while no significant association was found with stroke. Additionally, those with normal WC high BMI showed a 24.6% higher risk of CVD incidence (95% CI:1.046-1.483), and a 29.1% higher risk of heart disease incidence (95% CI:1.045-1.594), again with no significant association with stroke. Finally, individuals with central obesity high BMI exhibited a 49.3% higher risk of CVD incidence (95% CI:1.273-1.751), a 61% higher risk of heart disease incidence (95% CI:1.342-1.931), and a 34.2% higher risk of stroke incidence (95% CI:1.008-1.786). Age- and sex- specific analyses further revealed varying trends in these associations.
CONCLUSIONS: We discovered that the combined association of body mass index(BMI) and central obesity with CVD incidence exhibited a significantly enhanced predictive value. Specifically, a high BMI with central obesity was notably linked to an increased risk of CVD incidence. Additionally, central obesity with a normal BMI or a normal WC coupled with a high BMI significantly augmented the risk of heart disease incidence, but not stroke. Notably, male and middle-aged adults demonstrated a greater propensity for heart disease incidence. Our study underscores the importance of maintaining an optimal BMI and preventing abdominal obesity in promoting cardiovascular health.
In this time-matched comparison intervention, participants will be provided with an online copy of The Body Is Not An Apology Workbook by author and activist Sonya Renee Taylor (2021). Weekly emails will assign workbook activities to complete on their own (90 minutes per week for three weeks). This low-dissonance comparison intervention covers many of the same topics within the EVERYbody Project-Connect (body acceptance and scrutinizing the diversity within body ideals) and its activities include reflective writing and drawing exercises to challenge media messages around bodies, identify systems of oppression underpinning body messages, challenge body stereotypes, and make peace with your own body. Activities within the workbook are considered low-dissonance since they will be done privately and not shared.
The invention provides a begonia fimbristipula health-care food. The begonia fimbristipula health-care food has the health-care functions of reducing blood fat, reducing blood pressure, enhancing the immunity, nourishing and building the body, and the like, and is suitable for being eaten for a long term. The begonia fimbristipula has the efficacies of clearing away heat and toxic material, moistening the lung to arrest cough, dispelling fatigue and promoting the subsidence of swelling, and promoting the production of the body fluid to quench thirst, and is capable of treating diseases such as exogenous high fever, fever caused by sunstroke, cough with lung heat, coryza and trachyphonia, carbuncle and sore toxicity, and painful swelling from knocks and falls. The begonia fimbristipula is relatively rich in mineral nutrition and relatively high in content of nutritional ingredients such as trace elements calcium, manganese, ferrum, zinc and copper, and has the efficacies of improving the immunity of human bodies, clearing away heat and toxic material, promoting blood circulation and arresting bleeding, reducing blood pressure, reducing blood fat and regulating blood glucose. The proportional bulbus fritillariae cirrhosae, cortex ailanthi, Chinese chive seeds, fructus akebiae and disodium glycyrrhizinate are capable of enhancing the health-care efficacy of the begonia fimbristipula; especially in the aspect of reducing blood fat, the begonia fimbristipula health-care food is capable of reducing the contents of cholesterol and triglyceride in blood if being drunk for a long term. By use of the production process, the healthcare function of the begonia fimbristipula can be further enhanced, and the immunity of human bodies is further improved.
The pathways involved in the pathophysiology of fetal growth restriction (FGR) and small for gestational age (SGA) are incompletely understood. We conduct a systematic review to identify metabolomic signatures in maternal and newborn tissues and body fluids samples associated with FGR/SGA. Here, we report that 825 non-duplicated metabolites were significantly altered across the 48 included studies using 10 different human biological samples, of which only 56 (17 amino acids, 12 acylcarnitines, 11 glycerophosphocholines, six fatty acids, two hydroxy acids, and eight other metabolites) were significantly and consistently up- or down-regulated in more than one study. Three amino acid metabolism-related pathways and one related with lipid metabolism are significantly associated with FGR and/or SGA: biosynthesis of unsaturated fatty acids in umbilical cord blood, and phenylalanine, tyrosine and tryptophan biosynthesis, valine, leucine and isoleucine biosynthesis, and phenylalanine metabolism in newborn dried blood spot. Significantly enriched metabolic pathways were not identified in the remaining biological samples. Whether these metabolites are in the causal pathways or are biomarkers of fetal nutritional deficiency needs to be explored in large, well-phenotyped cohorts.
* The solution should be clear and colorless and may contain a small amount of easily visible, white, amorphous, cetuximab particulates. Do not shake or dilute. 
  * Visually inspect for foreign particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if solution is discolored, cloudy, or contains foreign particulate matter. 
  * Do not administer ERBITUX as an intravenous push or bolus. 
  * Administer via infusion pump or syringe pump. Do not exceed an infusion rate of 10 mg/min. 
  * Administer through a low protein binding 0.22-micrometer in-line filter.
The incidence of postoperative nausea and vomiting (PONV) remains high, and improving the accuracy of PONV prediction remains challenging. The primary aim of this study is to examine the impact of anxiety scores evaluated using the Hospital Anxiety and Depression Scale (HADS) on the PONV prediction model. We hypothesized that anxiety and depression, quantified using the HADS, could improve the accuracy of the PONV predictive model. This pilot study evaluated 100 patients. The HADS was conducted by a self-evaluation method before thoracoscopic surgery for lung tumors, and the anesthesia method was standardized. The criterion was whether the nurse in charge of the patient who complained of PONV assessed that drug administration was necessary. As the main analysis, the odds ratio of the HADS score for predicting PONV was evaluated using multivariable logistic regression models. Further, the receiver operating characteristic (ROC) curves of the model with the HADS score added to the variables of without-anxiety predictors and the model with the variables of without-anxiety predictors only were compared. The anxiety score was significantly higher in the PONV group than in the no PONV group (P = 0.021). For predictive accuracy, the model that included age, sex, smoking history, history of PONV, and anxiety score had a higher area under the ROC curve than did the model excluding the anxiety score (P = 0.021). In conclusion, the findings indicate that the HADS is worth investigating as a predictor of PONV.
PO valganciclovir (900 mg every 12 hours for 7 days followed by 900 mg every 24 hours for 7 days. If CMV viral load \<5000 copies/ml after 14 days then 900 mg every day until 21 total days of therapy. If CMV viral load \>5000 copies/ml after 14 days but less than the index viral load then 900 mg every day until 28 total days of therapy. If CMV viral load \>= the index viral load 900 mg every 12 hours for 7 days, if CMV viral load \<= to previous viral load then 900 mg every 12 hours for another 7 days.
The invention relates to the field of skin care, and in particular relates to a rose spot-fading mask, and preparation and use methods thereof. The materials selected for preparing the mask include Chinese angelica, peach seeds, dahurian angelica roots, mung beans, white poria, common bletilla pseudobulb, rose essential oil, and rose flower water. The preparation method comprises the following steps: 1, mixing 50g of each of the above traditional Chinese medicine powder together, and then bottling the mixed traditional Chinese medicine powder for later use; 2, putting 15g of the mixed traditional Chinese medicine powder from a bottle into a bowl for later use; 3, adding 200-240ml of the rose flower water, and mixing the powder and the rose flower water uniformly; and 4, adding 45ml of the rose essential oil, and mixing the materials uniformly. The mask is uniformly applied to a face by using a small brush, then is cleaned after 20-30 minutes, and is used for 2-3 times every week. The mask provided by the invention is suitable for skin activating and whitening maintenance for various types of skins, and is suitable in four seasons. The mask is particularly suitable for people of 25 or more than 25 years old with dark, black-spot and sallow mature skins, and has the effects of activating blood circulation, fading spots, and whitening and nourishing skins.
PROBLEM TO BE SOLVED: To obtain a new compound, a specific azole derivative, exhibiting excellent antimicrobial action against fungi including Trichophyton and candida, and useful as a medicament. SOLUTION: This new compound is a compound of the formula (R1 and R2 are each H, an alkyl or the like; X is N or CH; m is 0-2; n is 1-3), e.g. (2RS, 3RS)-2-(2,4-difluorophenyl)-3-(1,4-thiazinan-4-yl)-1-(1H-1,2,4-triazol -1-yl) butan-2-ol. The compound of the formula is obtained by reaction of a difluorophenyl compound with e.g. a compound of the formula R3SO2-SO2R3 (R3 is a lower alkyl or the like) in the presence of a base followed by reaction of a base with the resultant compound to form an epoxy compound which, in turn, is reacted with pref. 10-40 molar times of an amine derivative in water or an organic solvent pref. at 50-150 deg.C for 12-72 h.
Dyads randomized to the Immediate Intervention Group will receive a "Welcome Box" at completion of the baseline assessment. The Welcome Box will include two of each of the following: 1) Letters describing the project logistics and the important roles of each dyad member); 2) WiFi-enabled Scales (with instructions to weigh daily); 3) Portion Doctor ®Tableware (with instructions to use the portion plates at least once a day); 4) Fitbit® Inspire Activity Monitors (with instructions to share data with the dyad member and the study office); and 5) Instructions on how to create a secured account on the DUET website and instructions for logging on.
Intracerebral hemorrhage (ICH) induces a complex sequence of apoptotic cascades and inflammatory responses, leading to neurological impairment. Transient receptor potential vanilloid 1 (TRPV1), a nonselective cation channel with high calcium permeability, has been implicated in neuronal apoptosis and inflammatory responses. This study used a mouse ICH model and neuronal cultures to examine whether TRPV1 activation exacerbates brain damage and neurological deficits by promoting neuronal apoptosis and neuroinflammation. ICH was induced by injecting collagenase in both wild-type (WT) C57BL/6 mice and TRPV1-/- mice. Capsaicin (CAP; a TRPV1 agonist) or capsazepine (a TRPV1 antagonist) was administered by intracerebroventricular injection 30 min before ICH induction in WT mice. The effects of genetic deletion or pharmacological inhibition of TRPV1 using CAP or capsazepine on motor deficits, histological damage, apoptotic responses, blood-brain barrier (BBB) permeability, and neuroinflammatory reactions were explored. The antiapoptotic mechanisms and calcium influx induced by TRPV1 inactivation were investigated in cultured hemin-stimulated neurons. TRPV1 expression was upregulated in the hemorrhagic brain, and TRPV1 was expressed in neurons, microglia, and astrocytes after ICH. Genetic deletion of TRPV1 significantly attenuated motor deficits and brain atrophy for up to 28 days. Deletion of TRPV1 also reduced brain damage, neurodegeneration, microglial activation, cytokine expression, and cell apoptosis at 1 day post-ICH. Similarly, the administration of CAP ameliorated brain damage, neurodegeneration, brain edema, BBB permeability, and cytokine expression at 1 day post-ICH. In primary neuronal cultures, pharmacological inactivation of TRPV1 by CAP attenuated neuronal vulnerability to hemin-induced injury, suppressed apoptosis, and preserved mitochondrial integrity in vitro. Mechanistically, CAP reduced hemin-stimulated calcium influx and prevented the phosphorylation of CaMKII in cultured neurons, which was associated with reduced activation of P38 and c-Jun NH2-terminal kinase mitogen-activated protein kinase signaling. Our results suggest that TRPV1 inhibition may be a potential therapy for ICH by suppressing mitochondria-related neuronal apoptosis.
Drugs Metabolized by P450 2D6

The biochemical activity of the drug metabolizing isozyme cytochrome P4502D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7 to 10 % of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P4502D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P4502D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).

In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P4502D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P4502D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P4502D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).

Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P4502D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P4502D6.

Doxepin is primarily metabolized by CYP2D6 (with CYP1A2 & CYP3A4 as minor pathways). Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly. The extent of interaction depends on the variability of effect on CYP2D6. The clinical significance of this interaction with doxepin has not been systematically evaluated.
Fanconi anemia (FA) is a rare genetic disease that often presents as a bone marrow failure (BMF) syndrome but also can affect any other organ. Etiologically, loss of function mutations in more than 21 different gene members of the FA core complex (i.e. FANCA-FANCV) have been associated with FA. The FA core complex is involved in interstrand cross-link DNA damage repair during cell division. Impaired DNA repair causes genomic instability which consequently can cause apoptosis of the cell or malignant transformation. In addition to impaired DNA repair mechanisms, FA cells exhibit increased sensitivity to pro-inflammatory cytokines (e.g. IFN-gamma, TNF-alpha) and elevated levels of these cytokines have been associated with bone marrow failure in subjects with FA and other inherited bone marrow failure syndromes.

Patients with FA may present with congenital anomalies, such as microcephaly or short stature. However, the failure of the hematopoietic stem cell (HSC) compartment to produce sufficient numbers of peripheral blood cells, and progression to myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) are the greatest risk factors for morbidity and mortality, particular in young patients with FA. In a few reported cases, spontaneous somatic reversion of inherited mutations has resulted in a selective growth advantage of corrected HSCs that subsequently restored hematopoiesis. However, therapeutic options are limited in FA. Although HSC transplantation outcomes have significantly improved over the past two decades, donor availability, graft failure, and FA-specific transplant toxicities are still significant hurdles towards a curative treatment of FA-associated BMF. Moreover, attempts at genetic correction of FA are not yet ready for patient care.

The thrombopoietin (TPO) mimetic eltrombopag (EPAG) has recently been shown to be effective in restoring tri-lineage hematopoiesis in patients with treatment refractory acquired severe aplastic anemia (SAA). Of particular interest for patients with FA is the observation that EPAG also improves the repair of double strand DNA breaks, a mechanism that is impaired in patients with FA. Additionally, our pre-clinical studies indicate that EPAG evades INF-gamma blockade of signal transduction from the TPO receptor (cMPL) resulting in improved survival and proliferation of HSCs. Based on these clinical and pre-clinical studies, we hypothesize that EPAG will improve peripheral blood cell counts in patients with FA and thus reduce morbidity and mortality.

This phase II clinical trial proposes to treat patients with FA for 6 months with EPAG to assess safety and efficacy at improving hematological manifestations of FA. Responders at 6 months will be able to continue EPAG on the extension part of this protocol for an additional 3 years. During this time frame we anticipate further improvement of peripheral blood cells counts that will eventually result in the discontinuation of EPAG after a tapering period. Translational studies will explore EPAG effects on DNA repair activity, apoptosis, global transcriptome and TPO signaling pathways in patient s hematopoietic stem and progenitor cells (HSPCs).
The present invention relates to the technical field of the biological medicine. The present invention particularly relates to a targeted preparation comprising a liposome with the encapsulated contrast agent and the nucleic acid, and the present invention also comprises the preparation method, which is applied in diagnosis and therapy. The targeted preparation of the present invention can be applied in treatment and diagnosis for the human and animal diseases. After preparation of the liposome with the encapsulated contrast agent, the liposome suspension and the nucleic acid are cultivated at room temperature for 15 minutes to 24 hours. After sterilization, the targeted preparation is obtained. Measurement results comprising particle diameter distribution, electric microscope observation and zeta potential all demonstrate that the targeted preparation of the present invention possesses stable structure, no toxicity, safe degradation, which completely accords with requirement for the targeted vector. In the present invention the targeted preparation carrying the Apo-A-I gene or the SR-BI gene are obtained through preparation. Genetic therapy and the treatment effect detection are conducted on rats by using the preparation. The result displays that the targeted preparation has good genetic therapy effect and high safety property.